Antithymocyte globulin induces ex vivo and in vivo depletion of myeloid and plasmacytoid dendritic cells

Transplantation

Volumn 79, Issue 3, 2005, Pages 369-371

  Fang, Lubin ^a   Fehse, Boris ^a   Engel, Melanie ^a   Zander, Axel ^a   Kröger, Nicolaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Allogeneic stem cell transplantation; Antithymocyte globulin; Dendritic cells; GVHD

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CD123 ANTIGEN; CD14 ANTIGEN; CD16 ANTIGEN; CD33 ANTIGEN; CD85K ANTIGEN; CD86 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; ETOPOSIDE; FLUDARABINE; LYMPHOCYTE ANTIGEN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MELPHALAN; T6 ANTIGEN; THIOTEPA; THYMOCYTE ANTIBODY; TREOSULFAN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW CELL; CELL COUNT; CLINICAL ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; DENDRITIC CELL; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MANTLE CELL LYMPHOMA; MYELODYSPLASTIC SYNDROME; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMA CELL; PRIORITY JOURNAL; SERUM; T CELL DEPLETION;

ADULT; ANTILYMPHOCYTE SERUM; DENDRITIC CELLS; FEMALE; HUMANS; LEUKEMIA; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; MULTIPLE MYELOMA; REFERENCE VALUES; STEM CELL TRANSPLANTATION;

EID: 14544294115     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000150210.77543.1B     Document Type: Article

References (20)

1. Ferrara JL, Deeg HJ. Graft-versus-host disease. N Engl J Med 1991; 324(10): 667-674.
2. Waldmann H, Polliak A, Hale G, Or R, et al. Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet 1984; 2(8401): 483-486.
3. Kröger N, Sayer HG, Schwerdtfeger R, et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002; 100(12): 3919-3924. Epub 2002 Aug 08.
4. Zander AR, Kröger N, Schleuning M, et al. ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML). Bone Marrow Transplant 2003; 32(4): 355-361.
5. Mohty M, Bay JO, Faucher C, et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 2003; 102(2): 470-476. Epub 2003 Mar 20.
6. Rebellato LM, Gross U, Verbanac KM, et al. A comprehensive definition of the major antibody specificities in polyclonal rabbit antithymocyte globulin. Transplantation 1994; 57(5): 685-694.
7. Bonnefoy-Berard N, Revillard JP. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transplant 1996; 15(5): 435-442.
8. Bonnefoy-Berard N, Vincent C, Revillard JP. Antibodies against functional leukocyte surface molecules in polyclonal antilymphocyte and antithymocyte globulins. Transplantation 1991; 51(3): 669-673.
9. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285(5426): 412-415.
10. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271-296.
11. Liu YJ, Kanzler H, Soumelis V, et al. Dendritic cell lineage, plasticity and cross-regulation. Nat Immunol 2001; 2(7): 585-589.
12. Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997; 90(9): 3245-3287.
13. Arpinati M, Chirumbolo G, Urbini B, et al. Use of anti-BDCA-2 antibody for detection of dendritic cells type-2 (DC2) in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29(11): 887-891.
14. Klangsinsirikul P, Carter GI, Byrne JL, et al. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution. Blood 2002; 99(7): 2586-2591.
15. Monti P, Allavena P, Di Carlo V, et al. Effects of anti-lymphocytes and anti-thymocytes globulin on human dendritic cells. Int Immunopharmacol 2003; 3(2): 189-196.
16. Eiermann TH, Freitag S, Cortes-Dericks L, et al. Jurkat cell-reactive anti-thymocyte globulin assessed ex vivo by flow cytometry persists three weeks in circulation. J Hematother Stem Cell Res 2001; 10(3): 385-390.
17. Waller EK, Rosenthal H, Jones TW, et al. Larger numbers of CD4(bright) dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation. Blood 2001; 97(10): 2948-2956.
18. Arpinati M, Chirumbolo G, Urbini B, et al. Infusion of high numbers of G-CSF mobilized blood dendritic cells type 2 [DC-2] is associated with an increased rate of chronic GVHD in allogeneic PBSC transplantation. Blood 2002; 100: 419a.
19. Avery S, Bollard GM, Spencer A, et al. Type 2 dendritic cell [DC2] content in donor peripheral blood stem cell [PBSC] grafts is associated with improved survival following allogeneic transplantation. Blood 2002; 100: 138a.
20. Arpinati M, Green C, Heimfeld S, et al. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000; 95: 2484-2490.